Related Experiment Videos
A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine
Hamdy M Abdel-Rahman1, Nawal A el-Koussi, Gamal S Alkaramany
1Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Archiv Der Pharmazie
|November 13, 2004
Summary
Researchers developed novel HIV protease inhibitors using allophenylnorstatine (Apns) as a transition state mimic. Modifications at the P2 and P2
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Virology
Background:
- HIV protease is a key target for antiviral therapy.
- Dipeptide analogues can act as transition state mimics to inhibit protease activity.
- Previous KNI series inhibitors showed promise but required further optimization.
Purpose of the Study:
- To design and synthesize novel HIV protease inhibitors based on dipeptide analogues.
- To incorporate allophenylnorstatine (Apns) as a transition state mimic.
- To explore structure-activity relationships by varying substituents at P2 and P2' sites.
Main Methods:
- Synthesis of dipeptide precursors using N-Boc-Apns-OH and Boc-Dmt-P2' synthones.
- Deprotection and coupling reactions to form the target dipeptide analogues.
- Systematic variation of P2 (2,6-dimethylphenoxyacetyl or 3-hydroxy-2-methylbenzoyl) and P2' moieties.
Main Results:
- Successfully synthesized novel dipeptide analogues incorporating Apns.
- Series 8 analogues showed improved activity compared to series 7 analogues.
- Positional isomerism at the P2' site significantly impacted activity and polarity.
Conclusions:
- The designed dipeptide analogues are potential candidates for novel HIV protease inhibitors.
- The P2 moiety structure influences inhibitor activity.
- Optimizing P2' substituents is crucial for enhancing antiviral efficacy and pharmacokinetic properties.